Aim: To investigate the potential use of anti-inflammatory drugs in patients with acute myocardial infarction (MI). Materials and Methods: A comprehensive search was conducted in the scientometric databases PubMed, Scopus, Web of Science, and Google Scholar for data from peer-reviewed English-language studies on the use of anti-inflammatory drugs in patients with coronary artery disease (CAD) published over the past 10 years. Results: Data from recent scientific studies indicate that the assessment of markers of systemic inflammation, particularly hsCRP, in patients with CAD is no less important than that of the lipid profile. The use of anti-inflammatory agents is an important component of prognosis-modifying therapy, especially in clinically complex patients who experience recurrent index events despite baseline therapy. Currently, the most well-studied anti-inflammatory agent with a sufficient safety profile in patients with CAD, including those with acute MI, is colchicine. Conclusions: Measuring levels of inflammatory markers and using anti-inflammatory agents, particularly colchicine, in addition to baseline therapy in patients with acute MI to prevent recurrent index events is justified and promising.